At 52 weeks, the mean change in the KCCQ clinical summary score was 19.51.2 for the tirzepatide group compared to 12.71.3 for the placebo group (between-group difference, 6.9
These benefits and changes in eating habits can be life-changing for many people, but may not last if the medication is stopped
Your practitioner will review your symptoms, medical history, and any relevant test results before recommending an appropriate treatment protocol
What to know before trying a low-dose GLP-1 For patients considering a lower dose, the overall strategy matters as much as the dose itself
For instance, GS26A and GSSK2 have demonstrated beneficial effects in lowering obesity
www.pendulumlife.com Media Contact: Alafair Hall [email protected] 415-730-9044 SOURCE Pendulum Therapeutics